Alyeska Investment Group
UNCY icon

Alyeska Investment Group’s Unicycive Therapeutics UNCY Stock Holding History

Alyeska Investment Group’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-175,000
Closed -$1.01M – 679
2025
Q1 		$1.01M Hold
175,000
– – ﹤0.01% 438
2024
Q4 		$1.39M Sell
175,000
-50,000
-22% -$277K 0.01% 481
2024
Q3 		$918K Buy
+225,000
New +$904K ﹤0.01% 467

Other funds holding UNCY

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Alyeska Investment Group's UNCY Position: Q2 2025 in Review

Alyeska Investment Group sold out of Unicycive Therapeutics (UNCY) in Q2 2025, closing a stake of 175,000 shares — an estimated $1.01M sold.

Alyeska Investment Group first reported a position in UNCY in Q3 2024 and held it in 3 quarters. The position peaked at $1.39M in Q4 2024. 20 funds tracked by Wall St. Rank hold UNCY as of Q2 2025.

  • Alyeska Investment Group reported no remaining Unicycive Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Alyeska Investment Group sold 175,000 Unicycive Therapeutics shares in Q2 2025, an estimated $1.01M.
  • Alyeska Investment Group first reported a position in Unicycive Therapeutics in Q3 2024 and held it in 3 quarters.
  • Alyeska Investment Group's Unicycive Therapeutics position peaked at $1.39M in Q4 2024.
  • 20 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2025.

Based on Alyeska Investment Group's 13F filing for Q2 2025, filed 14 Aug 2025.